Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.
Press releases published on June 17, 2025
Aptose Provides Corporate Updates
GlobeNewswire
·
June 17, 2025
Announces short-term cash advance SAN DIEGO and TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company, announced today that the Company has secured …
Communiqué de presse : Sanofi place 1,5 milliard d’euros d’emprunts obligataires
GlobeNewswire
·
June 17, 2025
Sanofi place 1,5 milliard d’euros d’emprunts obligataires Paris, 17 juin 2025 - Sanofi annonce avoir placé avec succès une émission obligataire en 2 tranches (les « obligations ») pour un montant de 1,5 milliard d’euros : 750 millions d’euros d’ …
Press release: Sanofi successfully prices €1.5 billion bond issue
GlobeNewswire
·
June 17, 2025
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an …
Endogenex to Present Data on Endoscopic Procedure for Type 2 Diabetes at American Diabetes Association’s (ADA) 85th Scientific Sessions
GlobeNewswire
·
June 17, 2025
MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Endogenex, a clinical-stage medical device company dedicated to improving outcomes in individuals with type 2 diabetes (T2D), will present results from its REGENT-1 Australia clinical study at the American …
Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
GlobeNewswire
·
June 17, 2025
NEW YORK and MELBOURNE, Australia, June 17, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, …
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
GlobeNewswire
·
June 17, 2025
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating BE-Smart for use with esophageal brush cytology. …
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
GlobeNewswire
·
June 17, 2025
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE …
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
GlobeNewswire
·
June 17, 2025
CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial …
Eccogene to Report Preclinical Data with ECC4703, Showcasing Impact on Lean Muscle Sparing and Fat Loss in Combination with Semaglutide and Tirzepatide
GlobeNewswire
·
June 17, 2025
BOSTON and SHANGHAI, June 17, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that …
Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS
GlobeNewswire
·
June 17, 2025
CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to zagociguat for the treatment of MELAS (Mitochondrial Encephalomyopathy, Lactic …
Counslr Partners with Hacking HR to Provide 24/7 Mental Health Support for Members
GlobeNewswire
·
June 17, 2025
NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Hacking HR, the fastest growing global community of HR leaders and practitioners, announced its partnership with Counslr, a leading digital mental health company, to provide its US-based premium members with …
Microbix Attending & Presenting at Asia Pacific POC 2025
GlobeNewswire
·
June 17, 2025
MISSISSAUGA, Ontario, June 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is attending and presenting at the 2nd Asia Pacific Conference on …
Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East
GlobeNewswire
·
June 17, 2025
REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty …
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
GlobeNewswire
·
June 17, 2025
Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, …
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
GlobeNewswire
·
June 17, 2025
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once-daily oral therapy for neurodegenerative diseases VTX3232 …
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
GlobeNewswire
·
June 17, 2025
- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of …
Vireo Growth Inc. Provides Corporate Update Post Closing of All Merger Transactions
GlobeNewswire
·
June 17, 2025
MINNEAPOLIS, June 17, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), today announced a series of corporate updates following the closing of all its previously-announced definitive merger agreements, which …
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
GlobeNewswire
·
June 17, 2025
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was …
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
GlobeNewswire
·
June 17, 2025
New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibiting at European Society of Organ Transplantation (ESOT) …
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
GlobeNewswire
·
June 17, 2025
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in …